Multilineage-differentiating stress-enduring (MUSE) cells have moved from laboratory curiosity to human clinical trials faster than many other cell types in regenerative medicine. For patients researching regenerative options, understanding what has actually been studied — and what remains unproven — is essential. This guide summarizes the published clinical research on MUSE cells as of today.
What Makes MUSE Cells Trial-Worthy
MUSE cells were first characterized in 2010 by Dr. Mari Dezawa and colleagues at Tohoku University in Japan. They are a small subpopulation of cells, identified by the surface marker SSEA-3, that tolerate cellular stress and show the capacity to differentiate into multiple tissue types in laboratory models. Two properties attracted clinical researchers: MUSE cells appear to home toward damaged tissue — research by Yamada and colleagues in 2018 described a signaling pathway (S1P–S1PR2) that may guide this migration — and published studies to date have not reported tumor formation, a concern that has slowed other pluripotent-like cell types.
The First-in-Human Study
The first human trial of a MUSE cell product (known as CL2020) was reported by Noda and colleagues in 2020, in patients who had experienced a heart attack. The primary goal of a first-in-human study is safety, and the published report described the therapy as well tolerated in that small group. Early-phase studies like this cannot establish effectiveness — they are designed to determine whether larger studies are reasonable.
Stroke Research
Among the most discussed MUSE cell findings is a randomized, placebo-controlled trial in ischemic stroke reported by Niizuma and colleagues in 2023. In that study, a higher proportion of patients receiving the MUSE cell product achieved a meaningful functional improvement compared with the placebo group. The trial was small, and researchers emphasized that larger confirmatory studies are needed before firm conclusions can be drawn. Still, a placebo-controlled design is a meaningful step above the case reports that dominate much of regenerative medicine.
Other Conditions Under Study
Japanese research groups have registered or reported early trials of MUSE cell products in several other conditions, including:
- Spinal cord injury
- Amyotrophic lateral sclerosis (ALS)
- Epidermolysis bullosa, a severe genetic skin condition
- Neonatal hypoxic-ischemic brain injury
Most of these remain in early phases, with small enrollments focused primarily on safety. Results should be interpreted cautiously until peer-reviewed outcomes are published.
What the Trials Do Not Yet Show
No MUSE cell product is FDA-approved for any condition. The completed trials are small, mostly conducted in Japan, and none has yet established long-term effectiveness for any disease. Patients evaluating regenerative options should be wary of any provider who presents MUSE cell research as settled science — and equally wary of dismissing a field where randomized controlled data is beginning to accumulate.
How Springs Rejuvenation Approaches the Evidence
At Springs Rejuvenation, our physicians follow the MUSE cell literature closely and discuss it candidly during consultations, including what remains investigational. Patients considering regenerative care deserve an honest map of the evidence — where it is promising, and where it is still early. If you would like to review the current research and whether a regenerative consultation makes sense for you, our team is available at clinics in Miami, New York, Los Angeles, Atlanta, and Austin.
Disclaimer: This article is for educational purposes only and is not medical advice. Results may vary. Consult with a qualified medical professional. Our Stem Cell exosome formula is produced in an FDA approved lab, but is not an FDA approved therapy. It is currently in the experimental stages — all information provided is based on our experience with patients. Individual responses vary. Always consult a qualified physician to discuss whether regenerative options may be appropriate for your situation.